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Abstract
Background: This study aimed to increase cardiovascular disease (CVD) risk assessment in adult first degree relatives of
patients with premature ischaemic heart disease (PIHD) using written and verbal advice.
Methods: Design: A prospective, randomised controlled trial. Setting: Cardiovascular wards at three South Australian
hospitals. Cardiovascular risk assessments were performed in general practice. Participants: Patients experiencing PIHD
(heart disease in men aged <55 years or women aged < 65 years) and their first degree relatives. Intervention: Patients
distributed either general information about heart disease and written advice to attend their general practitioner (GP)
for CVD risk assessment or general information about heart disease only, to their first degrees relatives. Main outcome
measure: The primary outcome was the proportion of relatives who attended their GP for CVD risk assessment within
6 months of the patients’ PIHD event.
Results: One hundred forty four patients were recruited who had 541 eligible relatives; 97/541 (18 %) of relatives
agreed to participate. A larger number of intervention 41/55 (75 %) than control group 9/42 (21 %) [difference 53 %,
95 % CI 36 % - 71 %] relatives attended their GP for a CVD assessment, and 34 % of these had moderate to very high
5-year absolute risk for CVD.
Conclusion: This low cost intervention demonstrates that individuals who have a family history of PIHD and are at
moderate or high risk of CVD can be targeted for early intervention of modifiable risk factors. Further research is
required to improve the uptake of the intervention in relatives.
Trial registration: The trial was registered with the Australian Clinical Trials Registry (ACTRN), Registration ID
12613000557730.
Background
Cardiovascular disease (CVD) accounted for 34 % of all
deaths and 12 % of the total allocated health system ex-
penditure ($7.6 billion) in Australia in 2008 [1]. The most
common form of CVD, ischaemic heart disease (IHD),
was estimated to effect 3 % (685,000) of Australians in
2007–2008 [2]. First degree relatives of patients with
premature IHD (PIHD), defined as males aged < 55 years,
or females < 65 years, are at increased risk of CVD [3–5]
and are an ideal target for primary preventive measures [6].
The Joint Task Force of European and other Societies
on Coronary Prevention advised in 1994 and 1998 that
close relatives of patients with PIHD should be screened
for coronary risk factors [7, 8] and the US National
Cholesterol Education Program III (NCEP) also recom-
mends screening patients with a recognised family his-
tory [9]. However evidence from Europe and the US
indicates that relatives of patients with PIHD are being
overlooked in primary prevention and several studies
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have highlighted the potential benefits of focusing on
high-risk families [10, 11]. In the EUROASPIRE II family
survey [12], self-reported family screening occurred in
only 11.1 % of siblings and 5.6 % of children of 1289
index patients with PIHD.
The idea for this study arose from conversations
amongst a sub-group of investigators about successful
interventions aimed at known risk factors for IHD
such as smoking, hypertension and hyperlipidemia,
and the relative lack of studies concerning PIHD. At
the commencement of this study, there were no pub-
lished Australian guidelines that promoted screening
for families experiencing PIHD and at least anec-
dotally, no system for alerting general practitioners
(GPs) about familial risk. Targeting primary preven-
tion at families with a positive family history was seen
to be a potentially cost-effective strategy to tackle the
burden of IHD in Australia and all developed coun-
tries. This study aimed to ascertain if the provision of
written and verbal advice, promoting cardiovascular
risk assessment to first-degree relatives of patients with
PIHD, increased the proportion of relatives undertaking
cardiovascular risk assessment in general practice.
Methods
Trial design
A prospective, multicentre, randomised controlled trial
conducted in Adelaide, South Australia.
Ethics approval
The study was ethically approved by the Royal Adelaide
Hospital Research Ethics Committee and Flinders Clinical
Research Ethics Committee, and approved for conduct at
Flinders Private Hospital. All participants provided their
written, informed consent for participation in this study.
Inclusion and exclusion criteria
Men aged < 55 and women aged < 65 hospitalised with
their first PIHD event. An IHD event was defined as any
one of the following: non-ST-segment elevation myocar-
dial infarction (NSTEMI), ST-segment elevation myocar-
dial infarction (STEMI), unstable angina or coronary
revascularisation (coronary artery bypass grafting, coron-
ary angioplasty with or without coronary stenting).
First degree relatives (siblings and children) of the pa-
tient aged at least 18, without diagnosed IHD and resid-
ing in Australia.
Patients and relatives were excluded if they were: ter-
minally ill, experiencing dementia and/or other significant
cognitive impairment, unable to speak English, illiterate,
had any condition that their treating doctor believed
warranted intensive family follow-up and intervention, or
Aboriginal and living in a remote indigenous community.
Participant recruitment
Patients were recruited from tertiary care cardiovascular
wards at the two largest tertiary teaching hospitals in
South Australia: the Royal Adelaide Hospital, Flinders
Medical Centre and Flinders Private Hospital from July
2009 to February 2012, and were approached only after
discharge from coronary care units into a ward or were
stable after a revascularisation procedure.
Research nurses at each site approached patients hos-
pitalised with PIHD, discussed the study, provided
written information and obtained written, informed
consent. Potential participants were advised that the
study was about cardiovascular risk assessment in their
first degree relatives, and that by agreeing to participate
in the study that they would be required to forward
study information to their relatives. The nurse constructed
a family tree with information provided by the patients.
Data collected included: relative status (brother, sister,
son, daughter), age, initials, parent’s initials and age, and if
the relative had a diagnosis of IHD.
Treatment allocation
Following receipt of written consent from each patient,
the research nurse selected the next sequentially num-
bered, opaque and sealed envelope containing a com-
puter generated treatment allocation. Randomisation
was conducted for each recruitment site by a statistician
not involved in the study analyses. Random number
generation, with a 1:1 ratio using SAS (version 9.1 SAS
Institute, Cary, NC, USA) [13].) was based on a sample
size of 140 (accommodating up to 80 possible patient
recruits at each site). Patients were randomly allocated
to provide either the ‘intervention’ or the ‘control’ in-
formation packs to all of their participating first degree
relatives. Packs were given by the research nurse to the
patients, who then distributed them to relatives whilst
still in hospital or posted them to relatives at a later
date. All patients were blinded as to which information
pack they were providing to their relatives.
Intervention group
Intervention group relatives were provided with a con-
sent form, reply paid envelope and information sheet
that explained the reason for the study and provided a
brief explanation about PIHD, cardiovascular risk factors
and the benefits of risk factor assessment. It included a
recommendation that the relative make an appointment
to attend their general practitioner (GP) for a cardio-
vascular risk assessment (without cost to them). Com-
pletion and return by the GP to the study center of a
post-card included in the study pack was taken as evi-
dence of attendance. Using the participant’s age, sex,
blood pressure (mmHg), diabetes status, smoking status
and total cholesterol: HDL ratio as recorded by the GP,
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a 5-year absolute CVD risk value was calculated and
multiplied by 1.5 (e.g. 10 % increased to 15 %) to ac-
count for the pre-existing family history of premature
heart disease in all study participants [5]. The CVD risk
factor chart, placed on the reverse side of the postcard,
was derived from the New Zealand Guidelines Group,
Heart Foundation, Stroke Foundation and NZ Ministry
of Health [14] and is based on Framingham Study data.
The 5 year CVD risk was calculated by the GP and used
in their consultation with the GP, however the risk was
recalculated by research staff when the postcard was
returned, and this % used for data analysis.
Additionally, intervention relatives were advised to
contact the Heart Foundation for free telephone advice
about heart disease, and were given the option to receive
further telephone advice from a study doctor or study
nurse, according to their preference.
Control (usual care) group
Control group relatives were provided with a consent
form, reply paid envelope and information sheet that ex-
plained the reason for the study and provided a brief ex-
planation about PIHD and cardiovascular risk factors
only. It did not include a recommendation to attend
their GP for a cardiovascular risk assessment, contact
the Heart Foundation or the option of further advice
about heart disease from a doctor or nurse.
6 month follow-Up
Six months after consent, all consenting relatives were
contacted to assess events following their relative’s hos-
pitalisation with an IHD event (during the January 2010
to August 2012 follow-up period). The brief telephone
conversation ascertained whether in the last 6 months
there had been: GP attendance with a cardiovascular risk
assessment performed, any cardiovascular risk factors
identified, any lifestyle changes made and how these had
been managed by their GP. A brief follow-up question-
naire asking the same series of questions was posted to
participants unable to be reached by telephone, follow-
ing two attempts. After follow-up, control group rela-
tives were subsequently provided with the same written
information given to the intervention group.
Outcomes
The primary outcome of the study was the proportion of
relatives who attended their GP for cardiovascular risk
assessment within 6 months of the patients’ PIHD event.
Post card return and self-reported attendance in the
intervention group were compared with self-reported at-
tendance in the control group. A secondary outcome of
the study was the absolute cardiovascular risk of rela-
tives in the intervention group, calculated from the GP
supplied information on the returned postcard.
Sample size and statistical analysis
Sample size
The sample size calculation made the following assump
tions:
– 30 % of patients would agree to participate in the
study (of these approximately 10 % will die or
otherwise not be able to participate in the first
6 months of the study)
– each patient had on average, three first-degree relatives
(inclusive of sibling(s) and children)
– 20 % of relatives would be ineligible due to an
existing IHD diagnosis and 50 % of eligible relatives
would agree to participate in the study, allowing for
a design effect of 1.1 (using a family intra-cluster
correlation coefficient of 0.05, and an average cluster
size of 3, the design effect [15] is 1 + (3–1)*0.05 = 1.1)
– A maximum dropout rate for relatives in the order
of 10 % over the course of the study.
A total minimum sample size of 140 patients and 136
relatives was calculated as sufficient to detect an increase
of 25 % (absolute) in general practitioner attendance for
IHD risk-assessment, with 25 % of control group rela-
tives attending in the 6 months after the event, com-
pared with 50 % of relatives in the intervention group,
and allowing for a correlation of 0.25 with other covari-
ates (e.g. age, gender), with at least 80 % power (90 %
power for a one sided test) at the 5 % significance level.
Statistical analysis
We present means and frequencies to describe the base-
line characteristics of both patients and relatives assigned
to the control and intervention study groups. We used a
generalised linear model with an identity link and bino-
mial error, and generalised estimating equations, to esti-
mate the difference in proportions of relatives attending
their GP between two randomised groups, allowing for
clustering within family. No adjustments we made for
baseline covariates. Statistical analyses were performed
using SAS version 9.1 (SAS Institute, Cary, NC, USA) [13].
The authors of this paper had full access to all of the




From 347 patients approached for inclusion 144 (42 %),
aged between 26 and 63 years, 33 % female and 67 %
male, provided their written informed consent for par-
ticipation and were randomly allocated to intervention
(n = 73) or control (n = 71) arms. The remaining 203
(58 %) patients were not enrolled because either they did
not meet the inclusion criteria n = 137 (67 %), of whom
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n = 61 had pre-existing heart disease, declined to partici-
pate n = 24 (12 %) or did not participate for other rea-
sons n = 42 (21 %) which included 28 people living in
remote Aboriginal communities (Fig. 1).
Relatives
Patients collectively identified 541 first degree relatives
who met the inclusion criteria and could be invited for
participation in the study. A total of 288 intervention
and 253 control information packs were provided to
these relatives. Feedback at recruitment and at the
6 month follow-up indicated that some patients would
not send packs to all their relatives because they were
estranged from some or all of their siblings or children.
Ninety seven (97) relatives responded with their con-
sent for participation, intervention (n = 55) and control
(n = 42). Overall 18 % of relatives invited to participate
replied with consent (19 % and 17 % of the intervention
and control group relatives, respectively). Six month
follow-up telephone calls (or postal questionnaire, if un-
able to reach after 2 attempts) were completed for 93 %
(51/55) and 79 % (33/42) for the intervention and control
groups, respectively. Refer Table 1 for participant summary.
GP attendance for cardiovascular risk assessment
A larger number of intervention (75 %; 41/55) than control
group (21 %; 9/42) [difference 53 %, 95 % CI 36 % – 71 %]
relatives attended their GP for a cardiovascular risk assess-
ment within 6 months of consent (Fig. 2). A greater pro-
portion of control (41 %; 17/42) than intervention group
(15 %; 8/55) relatives did not see their GP at all during the
6 months study follow-up. A small number of control
(n = 7) and intervention (n = 1) group relatives visited
their GP after being contacted by the research team at
6 months (ascertained from late return of the GP post-
cards after the 6 month follow-up). Overall 14 % (41/
288) of relatives in the intervention group attended for
cardiovascular risk assessment compared with 3.5 % (9/
253) of control group relatives.
Absolute cardiovascular risk
A 5-year absolute CVD risk was calculated for all
intervention relatives who visited their GP during the
6 month follow-up period for whom a completed post-
card was returned (n = 38). The majority of relatives
who attended their GP for a cardiovascular risk assess-
ment had low absolute cardiovascular risk (66 %)
(Fig. 3); five-year absolute CVD risk was moderate, high
Fig. 1 Consort flow diagram for the heart health study
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or very high in the remaining 34 %. All moderate to very
high risk relatives were identified to be siblings (not chil-
dren) of the PIHD patients.
Discussion
The results of this study demonstrate that when simple
written advice is given to first degree relatives of patients
with PIHD 75 % undertake GP cardiovascular risk as-
sessment within 6 months compared to 21 % in the con-
trol group. In addition 34 % of relatives, all siblings,
were found to be at moderate to very high risk of CVD
in the next 5 years, which has important implications for
primary prevention in this group.
Although published guidelines recommend screening of
first degree relatives of patients with PIHD [16, 17] none
appear to have evidence based strategies for achieving this
in practice. Screening tends to be opportunistic [12] and
there is evidence that siblings and children are missing
out [10]. Based on our findings we would recommend that
such advice for relatives should be part of cardiac rehabili-
tation and when this is not available, be part of a discharge
package given to all patients with PIHD. Although it
might be tempting to focus only on siblings of patients,
who tended to have a higher absolute CVD risk, we be-
lieve that for children this might be an important moment
for behavioral change which should be reinforced by visit
to a general practitioner.
The feasibility of implementing family screening in a
hospital setting has been examined in a European study
[3]. Their results were similar to ours with 63.9 % of rel-
atives in the intervention group undergoing CVD risk
assessment compared to 25.4 % in the control group.
Whilst their participation rate was higher this may re-
flect the clustered study design, the role of enthusiastic
cardiologists as part of their intervention and potentially
how people access care in the Belgian health system.
Our intervention was successful in getting some mod-
erate and high CVD risk individuals to have a cardiovas-
cular risk assessment. Guidelines and review papers
recommend the use of absolute cardiovascular risk to
guide management of risk factors [18] and a reduction
in population absolute cardiovascular risk has been dem-
onstrated in an RCT of health checks [19]. Providing in-
formation to a first degree family member shortly after a
relative’s recent heart event could make the most of a
window of opportunity, where receptivity to a new
health message may promote ‘contemplation’, leading to
readiness and ‘preparation’ to take ‘action’, as identified in
the Transtheoretical Model of Health Behaviour Change
[20]. There is, of course, the potential to do harm by gen-
erating anxiety in relatives who are actually at low risk.
Given our finding that it was siblings who were found
to be moderate or high risk it may be appropriate to
limit dissemination of information to this group only.
Table 1 Summary of participating patients with PIHD (n = 144)
and their first degree relatives (n = 97)
Intervention Control Total
Patients, n 73 71 144
Male 50 46 96 (67 %)
Female 23 25 48 (33 %)
Age, range 26-63 30-65 26-65
Age, mean (SD) 49 (6.13) 51.1 (6.5) 50 (6.4)
First degree relatives, n (%)
Invited 288 253 541
- Sister 91 (32 %) 79 (31 %)
- Brother 93 (32 %) 72 (28 %)
- Daughter 54 (19 %) 60 (24 %)
- Son 50 (17 %) 42 (17 %)
Replied with consent 55 (19 %) 42 (17 %) 97 (18 %)
- Sister 26 16
- Brother 20 7
- Daughter 5 12
- Son 4 7
Fig. 2 Proportion of relatives who attended their GP for a cardiovascular risk assessment, Intervention (n = 55) versus Control (n = 42)
Stocks et al. BMC Family Practice  (2015) 16:116 Page 5 of 7
It has been estimated that in the UK 1,011 myocardial
infarctions (MI) could be prevented over 5 years if the
siblings of patients, who had been admitted to hospital
with an episode PIHD in one year, could be identified
and managed with a ‘polypill’ [6]. Using Australian fig-
ures for MI and the assumption that PIHD accounts for
20 % of all CVD then the equivalent Australian totals
(55,000 MIs/year) would be 712 preventable heart at-
tacks over 5 years. Clearly the first step in preventing
these heart attacks is identifying those at risk. Whilst
these figures may be optimistic, our intervention appears
to be a good investment in ‘best’ or at least ‘better’
practice.
Privacy and confidentiality laws usually limit the ability
of hospitals and treating physicians to make direct con-
tact with persons related to their patients. Our indirect
method circumvents this issue; however we did find that
some patients were estranged from either their siblings
or children. This appears to be a common issue and will
be difficult to overcome in clinical practice because it is
hard to argue for overriding concerns about the future
health of relatives when only a proportion are at moder-
ate or high risk.
Limitations
Because this study was conducted in two major teaching
hospitals in Adelaide and the majority of relatives lived
in South Australia the generalizability of the findings
may be limited. The study did include a mix of public
and private patients; however we cannot be sure that the
socio economic or educational status of our participants
truly reflects the general population. Ideally we would
have collected such data on all patients and relatives
however this had to be balanced against increasing the
burden of paperwork in both groups and therefore low-
ering the participation rate.
Ideally we would have used reduction in mortality or
at least absolute cardiovascular risk as the primary out-
come measure but the additional follow-up and time re-
quired were beyond the resources of this study. We were
interested in a ‘proof of concept’ that could be developed
further if proven to be feasible.
Our study potentially incentivised the GP visit by of-
fering to pay for any gap to ensure equity of access for
all, however if the intervention was applied in practice
any gap payment might reduce the number of relatives
seeking GP CVD risk assessment. Considering that ap-
proximately 80 % of all GP service are currently bulk
billed (at no cost to the patient) [21] the impact might
be limited and in addition there is mixed evidence that
financial incentives improve attendance rates for CVD
risk assessment [22].
We assessed 347 hospitalised patients for eligibility
and randomized 144. Clearly many ineligible patients
(137), those living in remote aboriginal communities
(28) and their first degree relatives would have a differ-
ent set of circumstances from those participating in a
trial. In addition there were some hospitalised patients
who were not approached because they were recruited
for other trials or were on the wards at weekends or hol-
idays. As with any other trial we have selected an eligible
population for whom the results are applicable and we
cannot make any inferences about the impact of the
intervention on these other groups who make up a sub-
stantial proportion of all PIHD patients and their relatives.
The participation rate of relatives was low but amongst
all relatives who were eligible to participate at least 10 %
(14 % versus 3.5 %) more in the intervention group
attended for cardiovascular risk assessment. A result, if
attendance for risk assessment is seen as beneficial and
given the low cost of the intervention, that makes provid-
ing information to patients to distribute to their relatives
Fig. 3 5 year absolute risk of cardiovascular disease (Intervention n = 38)
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worthwhile. The participation rates may have been low be-
cause: it was a research study that required consent, pa-
tients may not have forwarded the information on to
relatives, or reflects a lack of interest in preventive health
care. Equally relatives may have received the information
and acted upon it without formally being part of the study.
Unfortunately, due to ethical constraints, we could not
send reminders or follow up non-responders.
Conclusions
Providing simple written and verbal advice to patients
hospitalised with PIHD to distribute to their adult chil-
dren, brothers and sisters leads more people to have a
cardiovascular risk assessment by their GP. Given the
simplicity of the intervention, and the number of rela-
tives at moderate or high CVD risk who could benefit
from primary prevention, it is likely to be a cost effect-
ive way of reducing the burden of CVD in Australia
and all developed countries around the world. More
research is required to evaluate if the content of the
information provided improves response rates, what
mechanisms improve the distribution of information to
first degree relatives and how to encourage more rela-
tives to attend for CVD risk assessment.
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